Navigation Links
Amylin Pharmaceuticals to Webcast First Quarter Results
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2008 on Monday, April 21, 2008 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2008.

The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (888) 536-6007 (U.S./Canada) or (706) 758-4632 (international), Conference ID# 43245695. A replay of the call will also be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (800) 642-1687 (U.S./Canada) or (706) 645-9291 (international), Conference ID# 43245695.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Di
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... The bread and butter of Wisconsins economic growth will ... capital to transfer our best technology to the marketplace, ... and ensuring theres a 21st century infrastructure in place ... side to the equation, too, that may prove as ...
... a provider of supply chain execution (SCE) ... supplier compliance and inbound productivity by providing ASN ... Link and CatalystConnect SL are part of ... OAG (Open Application Group) XML interface standards. The ...
... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Software Enables Suppler Customer Data Integration 2
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Scientific progress in Huntington,s disease (HD) relies upon the ... the disease,s genetics and/or pathophysiology. Large animal models, such ... rodent models, including a larger brain that is amenable ... more human-like neuro-architecture. Three articles in the latest issue ...
... to osteoporosis are a major cause of disability or premature ... who have already suffered one fragility fracture; they are at ... others who have not fractured. Nevertheless health care ... these patients, leaving them exposed to debilitating and life-threatening secondary ...
... and wild plants has concluded they are under threat ... decline or loss could have profound environmental, human health ... services to about 75% of crop species and enable ... Pollination services provided by insects each year worldwide are ...
Cached Biology News:Large animal models of Huntington's disease offer new and promising research options 2Large animal models of Huntington's disease offer new and promising research options 3Large animal models of Huntington's disease offer new and promising research options 4New review sets international standards for best practice in fracture liaison services 2Cocktail of multiple pressures combine to threaten the world's pollinating insects 2
... Gelzyme is an agarose-digesting enzyme ... cleaves simple carbohydrate bonds in agarose ... longer gel. The remaining carbohydrate molecules ... manipulation. DNA isolated with Gelzyme enzyme ...
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Biology Products: